Prosecution Insights
Prosecution Insights
13 pending office actions • 7 art units • 12 examiners • 0 of 13 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 12 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 12 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (23%) |
| §102 only | 1 (8%) |
| §112 only | 1 (8%) |
| Double-patenting + other | 2 (15%) |
| No statute on record | 6 (46%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FETTEROLF, BRANDON J | 2 | 49.5% | +14.6% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.3% | +24.5% |
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 63.5% | +38.8% |
| FERGUSON, JALISA HOLMES | 1 | 70.0% | +56.3% |
| RODRIGUEZ, RAYNA B | 1 | 32.4% | +21.6% |
| ROBINSON, MIKHAIL O'DONNEL | 1 | 56.8% | +41.6% |
| HERNANDEZ, JACKSON J | 1 | 52.8% | +51.5% |
| HAVLIN, ROBERT H | 1 | 52.3% | +27.2% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 33.3% | +30.0% |
| WILLIS, DOUGLAS M | 1 | 82.6% | +19.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18015616 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | HERNANDEZ, JACKSON J | 238d overdue |
| 17788847 | AGENT FOR ADJUVANT THERAPY | KONOPELSKI SNAVEL, SARA ELIZABETH | 88d overdue |
| 18263613 | TREATING CANCER IN PATIENT WITH PTEN INACTIVATING MUTATION | WHITE, DAWANNA SHAR-DAY | 73d overdue |
| 18044236 | TREATMENT REGIMENS FOR EXON-20 INSERTION MUTANT EGFR CANCERS | ROBINSON, MIKHAIL O'DONNEL | 16d overdue |
| 17917765 | CANCER THERAPY USING 3,5-DISUBSTITUTED BENZENE ALKYNYL COMPOUND AND MEK INHIBITOR | HAVLIN, ROBERT H | 10d overdue |
| 17786504 | THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | WILLIS, DOUGLAS M | 3d overdue |
| 18563058 | TREATMENT METHODS FOR SUBJECTS WITH CANCER HAVING AN ABERRATION IN EGFR AND/OR HER2 | FETTEROLF, BRANDON J | 9d |
| 18253521 | Crystalline Forms of 4-amino-N-[4-(methoxymethyl)phenyl]-7-(1-methylcyclopropyl)-6-(3-morpholinoprop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide, Methods of Preparation, and uses Thereof | FETTEROLF, BRANDON J | 15d |
| Art Unit | Apps |
|---|---|
| 1626 | 5 |
| 1627 | 3 |
| 1629 | 1 |
| 1628 | 1 |
| 1658 | 1 |
| 1624 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18563058 | TREATMENT METHODS FOR SUBJECTS WITH CANCER HAVING AN ABERRATION IN EGFR AND/OR HER2 | FETTEROLF, BRANDON J | 1626 | Other | Non-Final OA | 9d | Pending | Nov 21, 2023 |
| 18263613 | TREATING CANCER IN PATIENT WITH PTEN INACTIVATING MUTATION | WHITE, DAWANNA SHAR-DAY | 1627 | Other | Non-Final OA | 73d overdue | Pending | Jul 31, 2023 |
| 18253521 | Crystalline Forms of 4-amino-N-[4-(methoxymethyl)phenyl]-7-(1-methylcyclopropyl)-6-(3-morpholinoprop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide, Methods of Preparation, and uses Thereof | FETTEROLF, BRANDON J | 1626 | §112 | Final Rejection | 15d | Pending | May 18, 2023 |
| 18253229 | Methods of Using 4-Amino-N-[4-(Methoxymethyl)Phenyl]-7-(1-Methylcyclopropyl)-6-(3-Morpholinoprop-1-YN-1-YL)-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carboxamide for the Treatment of Tumors | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | DPOther | Final Rejection | — | Pending | May 17, 2023 |
| 18253273 | BRAIN-MIGRATING TUMOR THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | FERGUSON, JALISA HOLMES | 1626 | DPOther | Final Rejection | 75d | Pending | May 17, 2023 |
| 18026515 | METHODS OF TREATING RIBONUCLEOTIDE REDUCTASE-RELATED DISEASES WITH A RIBONUCLEOTIDE REDUCTASE INHIBITOR | RODRIGUEZ, RAYNA B | 1628 | Other | Final Rejection | 23d | Pending | Mar 15, 2023 |
| 18044236 | TREATMENT REGIMENS FOR EXON-20 INSERTION MUTANT EGFR CANCERS | ROBINSON, MIKHAIL O'DONNEL | 1627 | §103 | Non-Final OA | 16d overdue | Pending | Mar 07, 2023 |
| 18015616 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | HERNANDEZ, JACKSON J | 1627 | Other | Non-Final OA | 238d overdue | Pending | Jan 11, 2023 |
| 17917765 | CANCER THERAPY USING 3,5-DISUBSTITUTED BENZENE ALKYNYL COMPOUND AND MEK INHIBITOR | HAVLIN, ROBERT H | 1626 | §103 | Final Rejection | 10d overdue | Pending | Oct 07, 2022 |
| 17788847 | AGENT FOR ADJUVANT THERAPY | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | Other | Non-Final OA | 88d overdue | Pending | Jun 24, 2022 |
| 17786504 | THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | WILLIS, DOUGLAS M | 1624 | Other | Final Rejection | 3d overdue | Pending | Jun 16, 2022 |
| 17434573 | CANCER THERAPY USING 3,5-DISUBSTITUTED BENZENE ALKYNYL COMPOUND AND IMMUNE CHECKPOINT INHIBITOR | CANELLA, KAREN A | 1643 | §102 | Final Rejection | 16d overdue | Pending | Aug 27, 2021 |
| 16627146 | CHEMOTHERAPY FOR CANCER USING AZABICYCLO COMPOUND | MCKOY, QUINCY ANDRE | 1626 | §103 | Final Rejection | 22d | Pending | Dec 27, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial